Skip to main content
SpringerLink
Log in

Drug treatment of dementia

  • Chapter
Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics

Part of the book series: Key Topics in Brain Research ((KEYTOPICS))

Summary

In a brief review it is shown that historically drug treatment of Alzheimer’s disease has addressed at first unspecific symptoms. The subsequent therapy with vasodilators reflected the understanding of the nature of the illness at the time. Another intellectual construction was derived from the amine deficiency hypothesis of depression (use of stimulants). The many subsequent efforts in the development of therapeutic progress based on morphological and biochemical deficits have demonstrated that all the simple cause/effect models are inappropriate. New concepts are matter for discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Baltes PB, Willis SL (1982) Plasticity and enhancement of intellectual functioning in old age: Penn State’s adult development and enrichment program (ADEPT). In: Craik FIM, Trehub SE (eds) Aging and cognitive processes. Plenum Press, New York, pp 353–389

    Chapter  Google Scholar 

  • Bartus RT, Dean RL, Beer B (1984) Cholinergic precursor therapy for geriatric cognition: its past, its present and a question of its future. In: Ordy JM, Harmann D, Alfin-Slater RB (eds) Nutrition in gerontology. Raven Press, New York, pp 191–225

    Google Scholar 

  • Bartus RT, Dean RL, Fisher SK (1986) Cholinergic treatment for age related memory disturbances: dead or barely coming of age. In: Crook T, Bartus R, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 421–450

    Google Scholar 

  • Bartus RT, Dean RL, Pontocorvo M, Flicker C (1985) The cholinergic hypothesis — a historical, current perspective and future direction. Ann NY Acad Sci 444: 332–358

    Article  PubMed  CAS  Google Scholar 

  • Bartus RT, Dean RL, Sherman KA, Friedman E, Beer B (1981) Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 2: 105–111

    Article  PubMed  CAS  Google Scholar 

  • Bowen DM (1981) Alzheimer’s disease. In: Davison AN, Thompson RMS (eds) The molecular basis of neuropathology. Edward Arnold, London, pp 64–69

    Google Scholar 

  • Bowen DM, Davison AN (1981) The neurochemistry of ageing and senile dementia: In: Matthews WB, Glaser GH (eds) Recent advances in clinical neurology, vol 3. Churchill Livingstone, Edinburgh

    Google Scholar 

  • Bowen D, Smith C, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophics. Brain 99: 459–496

    Article  PubMed  CAS  Google Scholar 

  • Branconnier RJ, Cole JO (1981) Effects of acute administration of trazodon and amitriptylin on cognition, cardiovascular function, and salivation in the normal geriatric subject. J Clin Psychopharmacol 1: 82S - 88S

    Article  Google Scholar 

  • Breyer-Pfaff U, Gaertner HJ (1987) Antidepressiva — Pharmakologie, therapeutischer Einsatz and Klinik der Depression. Wissenschaftliche Verlagsanstalt, Stuttgart

    Google Scholar 

  • Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5): 685 —700

    Google Scholar 

  • CGDA (1986) The Committee for “Geriatric diseases and asthenias” at BGA: impaired brain functions in old age. AMI-Hefte, 1. Bundesgesundheitsamt, Berlin

    Google Scholar 

  • Coper H, Schulze G (1987) Charakterisierung and Wirkungsmechanismen von Nootropika. In: Coper H, Heimann H, Kanowski S, Kunkel H (Hrsg) Hirnorganische Psychosyndrome im Alter III. Springer, Berlin Heidelberg New York Tokyo, S 3–10

    Chapter  Google Scholar 

  • Coper H, Herrmann WM (1988) Psychostimulants, analeptics, nootropics. An attempt to differentiate and assess drugs designated for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217

    Google Scholar 

  • Coper H, Jänicke B, Schulze G (1986) Biopsychological research on adaptivity across the life span of animals. In: Baltes PB, Featherman DL, Lerner RM (eds) Life-span development and behavior, vol 7. LEA, New Jersey, pp 207 —232

    Google Scholar 

  • Crook T, Bartus RT, Ferris ST, Gershon S (1986) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut

    Google Scholar 

  • Davies P (1985) A critical review of the role of the cholinergic system in human memory and cognition. Ann NY Acad Sci 444: 212–217

    Article  PubMed  CAS  Google Scholar 

  • De Smet Y, Ruberg M, Serdan M, Dubois B, L’Hermitte F Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164

    Article  Google Scholar 

  • Drachman DA, Leavitt J (1974) Human memory and cholinergic system. A relationship to aging? Arch Neurol 30: 113–121

    Article  PubMed  CAS  Google Scholar 

  • Drachmann DA (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27: 783–790

    Article  Google Scholar 

  • Duara R, Grady C, Haxby J, Ingar D, Sokoloff L, Margolin RH, Mauring RG, Cutler NR, Rapoport SH (1984) Human brain glucose utilization and cognitive function in relation to age. Ann Neurol 16: 702–713

    Article  CAS  Google Scholar 

  • Ferris SH, Reisberg B, Crook T (1982) Pharmacologic treatment of senile dementia: choline, L-dopa, piracetam, and choline plus piracetam. In: Corkin S (ed) Alzheimer’s disease: a report of progress. Raven Press, New York, pp 475–481

    Google Scholar 

  • Flood JF, Cherken A (1988) Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice. Neurobiol Aging 9: 5–8

    Article  PubMed  CAS  Google Scholar 

  • Ghoneim MM, Mewaldt SP (1975) Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologia 44: 257–262

    Article  PubMed  CAS  Google Scholar 

  • Giurgea CE (1972) Vers une pharmacologie de l’activité intégrative du cerveau. Tentative du concept nootrope en psychopharmacologie. Actual Pharmacol 25: 115–157

    CAS  Google Scholar 

  • Hock FJ (1987) Drug influences on learning and memory in aged animals and humans. In: Mendlewicz J, Pull, Janke W, Kunkel H (eds) Biological psychology/pharmacopsychology. Karger, Basel, pp 145–160

    Google Scholar 

  • Hollander E, Mohs RC, Davis KL (1986) Cholinergic approaches to the treatment of Alzheimer’s disease. Br Med Bull 42: 97–100

    PubMed  CAS  Google Scholar 

  • Hollister LE (1986) Summary and conclusions. In: Crook Th, Bartus RT, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 671–677

    Google Scholar 

  • Hollister LE (1986) Drug therapy of Alzheimer’s disease: realistic or not? Prog Neuropsychopharmacol Biol Psychiatry 10: 439–446

    Article  PubMed  CAS  Google Scholar 

  • Hoyer S (1986) Senile dementia and Alzheimer’s disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 10: 447–478

    Article  PubMed  CAS  Google Scholar 

  • Jacobsen A (1958) The use of Ritalin in psychotherapy of depression of the aged. Psychiatr Q 32: 475–483

    Google Scholar 

  • Kalinowsky LB, Hippius H (1969) Pharmacological, convulsive and other somatic treatments in psychiatry. Grune and Stratton, New York

    Google Scholar 

  • Kopelman MD, Lishman WA (1986) Pharmacological treatments of dementia (non cholinergic). Br Med Bull 42: 101–105

    PubMed  CAS  Google Scholar 

  • Kraepelin E (1910) Das senile and präsenile Irresein; in Psychiatrie. Ein Lehrbuch für Studierende and Ärzte. Verlag Johann Ambrosius Barth, Leipzig

    Google Scholar 

  • Lassen NA (1959) Cerebral blood flow and oxygen consumption in man. Physiol Rev 39: 183–238

    PubMed  CAS  Google Scholar 

  • Loew DM, Singer JM (1983) Stimulants and senility. In Cresse I (ed) Neuro-chemical behavioral and clinical perspectives. Raven Press, New York, pp 237–268

    Google Scholar 

  • Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 228: 1115–1117

    Article  PubMed  CAS  Google Scholar 

  • Mohs RC, Davis BM, Greenwald BS, Mathé AA, Johns CA, Horvath ThB, Davis KL (1985) Clinical studies of the cholinergic deficit in Alzheimer’s disease. II. Psychopharmacologic studies. Am Geriatr Soc 33: 749–757

    Google Scholar 

  • Narang PK, Cutler NR (1986) Pharmacotherapy in Alzheimer’s disease: basis and rationale. Prog Neuropsychopharmacol Biol Psychiatry 10: 519–531

    Article  PubMed  CAS  Google Scholar 

  • Obrist WD (1979) Cerebral circulatory changes in normal aging and dementia. In: Hoffmeister F Müller D (eds) Brain function in old age. Springer, Berlin Heidelberg New York, pp 278–287

    Chapter  Google Scholar 

  • Parnetti L, Ciuffetti G, Mercuri M, Senin U (1985) Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline. Arch Gerontol Geriatr 4: 141–155

    Article  PubMed  CAS  Google Scholar 

  • Perlick D, Stastny P, Katz I, Mayer M, Mattis St (1986) Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 143: 230–232

    PubMed  CAS  Google Scholar 

  • Pilch H, Müller WE (1988) Piracetam elevates muscarinic chclinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology 94: 74–78

    Article  PubMed  CAS  Google Scholar 

  • Plotkin DA, Jarvik LF (1985) Cholinergic dysfunction in Alzheimer disease: cause or effect? In: van Ree JM, Matthysse S (eds) Prog Brain Res 65: 91–103

    Chapter  Google Scholar 

  • Rogers RL, Meyer JS, Mortel KF, Mahurin RK, Judd BW (1986) Decreased cerebral blood flow precedes multi-infarct dementia, but follows senile dementia of Alzheimer type. Neurology 36: 1–6

    Article  PubMed  CAS  Google Scholar 

  • Sadeh M, Braham J, Modau M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667

    Article  PubMed  CAS  Google Scholar 

  • Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer-type. N Engl J Med 315: 1241–1245

    Google Scholar 

  • Szelies B, Herholz K, Pawlik G (1986) Zerebraler Glukosestoffwechsel bei präseniler Demenz vom Alzheimer Typ — Verlaufskontrolle unter Therapie mit muskarinergem Cholinagonisten. Fortschr Neurol Psychiatr 54: 364–373

    Article  PubMed  CAS  Google Scholar 

  • Tachibana H, Meyer JS, Kitagawa Y, Rogers RL, Okayasu H, Mortel KF (1984) Effects of aging on cerebral blood flow in dementia. J Am Geriatr Soc 32: 114–120

    PubMed  CAS  Google Scholar 

  • Tomlinson BE, Blessed G, Roth M (1970) Observation on the brains of demented old people. J Neurol Sci 11: 205–242

    Article  PubMed  CAS  Google Scholar 

  • Yesavage JA, Tinkelenberg JR, Berger PA, Hollister LE (1979) Vasodilators in senile dementia: a review of the literature. Arch Gen Psychiatry 36: 220–223

    Article  PubMed  CAS  Google Scholar 

  • Yoshikawa M, Hirai S, Aizawa T, Kuroiwa Y, Goto F, Sotue I, Idia M, Toyokura Y, Yamamura H, Iwasaki Y (1983) A dose response study with dihydroergotoxine mesylate in cerebrovascular disease. J Am Geriatr Soc 31: 1–7

    PubMed  CAS  Google Scholar 

  • Zornetzer StF (1986) The noradrenergic locus coeruleus and senescent memory dysfunction. In: Crook T, Bartus R, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 337–359

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropsychopharmacology, Free University Berlin, Germany

    Dr. H. Coper

Authors
  1. Dr. H. Coper
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry, University of Würzburg, Würzburg, Federal Republic of Germany

    Konrad Maurer , Peter Riederer  & Helmut Beckmann ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Wien

About this chapter

Cite this chapter

Coper, H. (1990). Drug treatment of dementia. In: Maurer, K., Riederer, P., Beckmann, H. (eds) Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics. Key Topics in Brain Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3396-5_62

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3396-5_62

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82197-8

  • Online ISBN: 978-3-7091-3396-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation